Last updated: September 2, 2026
Choline fenofibrate, marketed primarily as Trilipix, is a mature prescription lipid-lowering product with limited remaining commercial value. The drug is the choline salt of fenofibric acid and was developed as a delayed-release alternative to older fenofibrate formulations. Its commercial trajectory followed a familiar pattern: rapid uptake after FDA approval, use in combination with statins, erosion after generic fenofibrate competition, and declining branded revenue after loss of market exclusivity.
The product is no longer a major growth asset. Generic fenofibric acid capsules and competing fenofibrate products have compressed pricing, while clinical demand has shifted toward statins, omega-3 therapies, and newer cardiovascular-risk treatments.
What is choline fenofibrate and how does it work?
Choline fenofibrate is a fibrate-class drug that is converted to fenofibric acid, the pharmacologically active moiety. Fenofibric acid activates peroxisome proliferator-activated receptor alpha, or PPAR-alpha. This increases lipoprotein lipase activity, reduces hepatic production of very-low-density lipoprotein, and changes triglyceride and high-density lipoprotein metabolism.
Trilipix was supplied as delayed-release capsules in 45 mg and 135 mg strengths. The product was approved for use with diet in adults with:
- Severe hypertriglyceridemia.
- Primary hypercholesterolemia or mixed dyslipidemia.
- Mixed dyslipidemia in combination with a statin in selected patients.
The FDA label warns about myopathy, rhabdomyolysis, hepatic toxicity, renal effects, gallbladder disease, and interactions with statins and anticoagulants. Fenofibrate-class drugs have also faced questions about cardiovascular-outcome benefits relative to statin therapy. The product was positioned mainly as an adjunct to statins and diet rather than as a replacement for first-line statin treatment (U.S. Food and Drug Administration [FDA], 2008).
When was Trilipix approved and how did the product enter the market?
Abbott Laboratories received FDA approval for Trilipix in December 2008 under NDA 022224. The approval relied on the established pharmacology of fenofibric acid and positioned the product as a treatment for dyslipidemia and severe hypertriglyceridemia.
Abbott later transferred the product portfolio to AbbVie following the 2013 separation of the two companies. Trilipix was part of Abbott’s established cardiovascular and metabolic products, but it did not become a core long-term growth brand for AbbVie.
| Milestone |
Event |
| December 2008 |
FDA approval of Trilipix |
| 2009-2012 |
Commercial expansion in dyslipidemia and statin-combination use |
| 2013 |
Abbott separates pharmaceutical operations into AbbVie |
| Early-to-mid 2010s |
Generic fenofibrate and fenofibric-acid competition intensifies |
| Mid-to-late 2010s |
Branded sales decline as price competition expands |
| Current market position |
Mature genericized fibrate market with limited branded pricing power |
The initial commercial rationale was stronger than the long-term market outcome. Trilipix offered a newer formulation and a differentiated fenofibric-acid presentation, but these advantages did not create a durable barrier once generic fibrate products became widely available.
What was the financial trajectory for choline fenofibrate?
Trilipix generated meaningful revenue during the early post-launch period, but public company disclosures did not consistently report the product as a standalone revenue line. Abbott and AbbVie commonly grouped Trilipix with broader pharmaceutical or lipid-management portfolios. As a result, precise annual global revenue figures are not available from a consistent public reporting series.
The commercial trajectory can be divided into four phases:
Launch and adoption
The product benefited from the established use of fibrates and from promotion to physicians treating patients with mixed dyslipidemia. The 45 mg and 135 mg dosage strengths supported titration and use in patients with renal impairment.
Trilipix also benefited from co-prescription with statins. The combination strategy addressed patients whose triglyceride levels or HDL levels remained abnormal despite statin treatment.
Peak commercial period
The product reached its highest commercial relevance in the early 2010s. It competed in a market with established fenofibrate products, including branded and generic formulations of Tricor and related products.
Revenue was supported by brand recognition, physician familiarity, and the clinical convenience of delayed-release capsules. The product’s position was weaker in markets where generic fenofibrate was already available at substantially lower prices.
Generic erosion
Generic competition reduced both volume and average selling price. Payers increasingly preferred generic fenofibrate and fenofibric acid products. Pharmacy benefit managers had limited incentive to preserve a premium for Trilipix because the active pharmacologic component was well established.
Unlike specialty drugs, choline fenofibrate did not have a complex administration system, biologic manufacturing process, or difficult-to-replicate delivery device. This limited the product’s ability to retain premium pricing after patent and regulatory barriers weakened.
Mature decline
By the late 2010s and early 2020s, choline fenofibrate had become a low-growth or declining product category. Any remaining branded demand was likely concentrated in patients who were stable on the branded product, had prescriber preference, or faced formulary-specific access conditions.
The relevant financial metric is no longer peak branded revenue. It is residual generic-market volume, channel pricing, manufacturing cost, and the ability to maintain supply contracts.
How large is the choline fenofibrate market?
The market is fragmented across several related products:
| Segment |
Representative products |
Commercial position |
| Choline fenofibrate |
Trilipix; generic fenofibric acid delayed-release capsules |
Mature, price-sensitive |
| Fenofibrate |
Tricor and multiple generics |
Larger and more established generic segment |
| Fenofibrate tablets or capsules |
Multiple generic manufacturers |
Broad pharmacy access |
| Fenofibric acid formulations |
Generic delayed-release capsules |
Direct competition with Trilipix |
| Other triglyceride therapies |
Icosapent ethyl, omega-3 products, statins |
Compete for treatment decisions |
The addressable market is constrained by clinical practice. Statins remain the main pharmacologic treatment for atherosclerotic cardiovascular risk, while fibrates are generally used for severe hypertriglyceridemia or selected mixed-dyslipidemia patients. Icosapent ethyl has also captured attention in patients with elevated triglycerides and established cardiovascular risk.
Choline fenofibrate therefore competes against both same-class generics and alternative treatment strategies. Its relevant market is narrower than the overall dyslipidemia market.
What patents protected Trilipix and choline fenofibrate?
The original protection strategy covered the fenofibric-acid active ingredient, pharmaceutical compositions, and delayed-release delivery. The principal commercial value came from formulation and salt selection rather than from a novel therapeutic mechanism.
Formulation protection
The product used a delayed-release capsule designed to deliver fenofibric acid through the gastrointestinal tract. Formulation patents could cover:
- The choline salt of fenofibric acid.
- Delayed-release or enteric-release particles.
- Particle-size and dissolution characteristics.
- Capsule compositions.
- Manufacturing processes for the active pharmaceutical ingredient and finished dosage form.
Formulation patents can delay generic entry, but they usually provide a narrower barrier than a composition-of-matter patent. Generic companies may challenge the claims, design around specific excipients, or rely on an alternative release profile if the regulatory pathway permits it.
Method-of-use protection
Trilipix labeling included treatment of severe hypertriglyceridemia, primary hypercholesterolemia or mixed dyslipidemia, and certain statin-combination uses. These indications could support method-of-use patent claims.
Method-of-use protection is commercially weaker when the underlying drug is already available in generic form. Generic manufacturers may use skinny-label strategies that omit patented indications, although enforcement depends on the claim language, label content, prescribing patterns, and inducement evidence.
Patent expiry and generic entry
The commercial exclusivity period ended well before the present market period. Generic fenofibric acid products entered the U.S. market after ANDA approvals and patent challenges involving the relevant branded products. The practical effect was a rapid reduction in Trilipix’s ability to command a premium.
The FDA Orange Book remains the primary source for the exact patent listings, expiration dates, pediatric extensions, and any relevant exclusivity codes associated with NDA 022224 (FDA, n.d.-a). Because Orange Book entries can change through patent-listing updates and product-status changes, the current listing should be evaluated directly when assessing a litigation or launch decision.
What is the Orange Book status of choline fenofibrate?
Trilipix was approved under NDA 022224. Generic fenofibric acid delayed-release capsules were approved through ANDA pathways referencing the branded product.
The regulatory issues most relevant to market participants are:
- Whether Trilipix remains listed as an active reference product.
- Which patents were listed against the NDA at the time of each ANDA filing.
- Whether generic applicants filed Paragraph IV certifications.
- Whether any 30-month litigation stays were triggered.
- Whether the generic label omitted protected indications.
- Whether the branded product remains commercially available through the same marketing authorization holder.
FDA Drugs@FDA and the Orange Book provide the controlling public regulatory record. A genericized small-molecule product does not create biosimilar risk because biosimilar provisions apply to biologics, not conventional chemical drugs (FDA, n.d.-a; FDA, n.d.-b).
Which companies challenge or compete with choline fenofibrate?
The competitive field includes generic manufacturers of fenofibrate and fenofibric acid. Depending on the period and dosage form, competitors have included large generic suppliers such as Teva, Mylan, Sandoz, Zydus, Lupin, Dr. Reddy’s Laboratories, and Amneal, together with other ANDA holders and contract manufacturers.
The principal competitive threats are:
- Lower-priced generic fenofibrate.
- Generic fenofibric acid delayed-release capsules.
- Alternative formulations with comparable dosing.
- Icosapent ethyl in patients with elevated triglycerides and cardiovascular risk.
- Statin intensification and combination therapy.
- Pharmacy benefit manager substitution and formulary exclusion.
The market does not have the litigation profile of a biologic or a highly complex drug-device product. Litigation risk is primarily associated with patent certification, formulation claims, manufacturing patents, and commercial launch timing.
What generic entry risks exist for choline fenofibrate?
Generic entry risk is high because the active ingredient is well characterized and the dosage form is a conventional oral capsule. The main barriers are regulatory equivalence, dissolution testing, manufacturing consistency, and any remaining formulation claims.
A generic entrant can use several launch strategies:
At-risk launch
A company may launch before all patent disputes are resolved after making a Paragraph IV certification. This creates potential damages exposure and an injunction risk, but it can accelerate market access if the challenger prevails or the patent is found unenforceable.
Label carve-out
A generic may omit a patented method-of-use indication from its label. This strategy is more practical when the protected use is separable from the unpatented indications and when the product’s commercial demand does not depend on the carved-out use.
Post-exclusivity launch
A company may wait until patent expiry or settlement-provided entry. This approach reduces litigation risk but may surrender first-mover economics in a market where several generic competitors can launch simultaneously.
Because choline fenofibrate has no biologic exclusivity framework, the commercial timing depends on small-molecule patent terms, FDA approval status, settlements, and the number of ANDA applicants.
How strong is the patent estate for choline fenofibrate?
The estate is commercially weak at the current stage of the product life cycle. Its earlier value came from formulation differentiation and branded market access. Those advantages decline sharply after:
- Expiration of key formulation patents.
- Approval of multiple ANDAs.
- Loss of formulary preference.
- Availability of generic fenofibrate alternatives.
- Absence of a difficult-to-copy delivery device.
- Limited clinical differentiation from older fibrates.
The remaining IP value, if any, is likely concentrated in manufacturing efficiency, process know-how, supplier qualification, and regulatory file maintenance rather than in enforceable market exclusivity.
What manufacturing and IP barriers remain?
Manufacturing barriers are moderate rather than high. A supplier must control:
- Fenofibric-acid assay and impurity profile.
- Salt formation with choline.
- Particle size and polymorphic characteristics.
- Delayed-release coating uniformity.
- Dissolution performance across pH conditions.
- Stability of the finished capsule.
- Scale-up reproducibility.
These factors can affect ANDA approval and product quality, but they do not generally prevent competition. The manufacturing process is more accessible than the production of a biologic, sterile injectable, long-acting depot, or complex drug-device combination.
What is the outlook for choline fenofibrate revenue?
The revenue outlook is stable to declining, with limited prospects for a branded rebound. Growth would require a new clinical indication, a differentiated combination product, a new delivery system, or a meaningful change in treatment guidelines. None of these is inherent in the current product profile.
The most likely commercial outcomes are:
| Scenario |
Market effect |
| Continued generic competition |
Further price compression and low branded revenue |
| Supply consolidation |
Temporary price increases if manufacturers exit |
| Renewed triglyceride-treatment demand |
Volume growth without equivalent revenue growth |
| New cardiovascular-outcome evidence |
Possible use expansion, but clinical evidence would be required |
| New formulation or combination product |
Potential niche premium pricing |
| Brand discontinuation |
Generic substitution with limited patient disruption |
For investors and licensing teams, choline fenofibrate is primarily a mature-product or manufacturing opportunity. It is not an attractive conventional specialty-pharma growth asset absent a new formulation, geographic expansion, or differentiated clinical positioning.
What is the competitive position versus fenofibrate and icosapent ethyl?
| Attribute |
Choline fenofibrate |
Generic fenofibrate |
Icosapent ethyl |
| Drug class |
Fibrate |
Fibrate |
Purified omega-3 fatty acid |
| Main use |
Triglycerides and mixed dyslipidemia |
Triglycerides and mixed dyslipidemia |
Elevated triglycerides in selected high-risk patients |
| Formulation |
Delayed-release capsule |
Multiple oral forms |
Capsules |
| Generic competition |
Yes |
Extensive |
More limited historically, now increasing |
| Differentiation |
Salt and release profile |
Low cost and availability |
Cardiovascular-outcome positioning |
| Patent strength today |
Limited |
Generally limited |
Product-specific patent and litigation history |
| Revenue outlook |
Mature or declining |
Volume-led, low margin |
Greater commercial potential in outcome-driven use |
Choline fenofibrate’s main advantage is familiarity and availability. Its principal weakness is the absence of strong differentiation once price-sensitive generic substitution becomes available.
Key Takeaways
- Choline fenofibrate is the active pharmaceutical component associated with Trilipix, a delayed-release lipid-lowering product.
- Abbott launched Trilipix in 2008; AbbVie inherited the product after the 2013 corporate separation.
- The product’s early commercial value came from formulation, salt selection, and combination use with statins.
- Generic fenofibrate and generic fenofibric acid materially weakened the branded franchise.
- The product is not a biologic and has no biosimilar-specific exclusivity risk.
- Patent value is concentrated in formulation, method-of-use, and manufacturing claims rather than a durable composition-of-matter barrier.
- Public company reporting did not consistently disclose standalone Trilipix revenue, limiting precise year-by-year financial reconstruction.
- Current revenue potential is low and generally depends on generic volume, supply conditions, and manufacturing economics.
- The product is more relevant as a mature generic, licensing, or supply opportunity than as a growth pharmaceutical asset.
FAQs About Choline Fenofibrate Market and Patent Economics
Is choline fenofibrate the same as fenofibrate?
No. Choline fenofibrate is a salt form that delivers fenofibric acid, while fenofibrate is a related ester compound that is metabolized to fenofibric acid. Both belong to the fibrate class but may differ in formulation, dosing, and regulatory labeling.
Is Trilipix still commercially important?
No. Trilipix has limited commercial importance compared with its early post-launch period because generic fenofibrate and fenofibric acid products are available and payers favor lower-cost alternatives.
Does choline fenofibrate have biosimilar competition?
No. Choline fenofibrate is a conventional small-molecule drug. Competition occurs through generic ANDA products rather than biosimilar applications.
Can a generic company launch fenofibric acid before all patents expire?
Potentially. A generic applicant may file a Paragraph IV certification, pursue an at-risk launch, or use a label carve-out for patented indications. Litigation, settlement terms, and the specific Orange Book patents determine the commercial timing.
Is choline fenofibrate an attractive licensing opportunity?
Usually only in narrow circumstances. Potential value may exist in low-cost manufacturing, regional distribution, authorized-generic arrangements, or a new combination or delivery system. The existing branded product alone has limited growth potential.
References
-
Abbott Laboratories. (2009-2012). Annual reports and pharmaceutical product disclosures. Abbott Laboratories.
-
AbbVie Inc. (2013-2023). Annual reports and securities filings. AbbVie Inc.
-
U.S. Food and Drug Administration. (2008). Trilipix prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.-a). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (n.d.-b). Drugs@FDA: FDA-approved drugs database. FDA.
-
U.S. Food and Drug Administration. (n.d.-c). Approved drug products and abbreviated new drug applications. FDA.
-
U.S. Food and Drug Administration. (2018). Fenofibrate and fenofibric acid product labeling and safety information. FDA.
